D. Storey

A real-world, long-term experience on effectiveness and safety of vedolizumab in adult patients with inflammatory bowel disease: The Cross Pennine study.

C. Stansfield, C. Selinger, J. Limdi, 2018, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

P147 Safety and efficacy of ustekinumab for Crohn’s disease (CD): the cross pennine experience

Rachael C. Walker, C. Stansfield, C. Selinger, 2021, Posters.

Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study

A. Kneebone, P. Collins, M. Dibb, 2022, Journal of Crohn's & colitis.

Comparative effectiveness of antitumour necrosis factor agents and vedolizumab in ulcerative colitis

S. Dodd, P. Collins, C. Probert, 2019, European journal of gastroenterology & hepatology.

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.

Diane M. Miller, Natalia E. Shilkina, M. C. Cantero, 2018, Lancet.

Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti‐TNF‐refractory Crohn’s disease

Philip Smith, K. Bodger, S. Dodd, 2020, Alimentary pharmacology & therapeutics.

A propensity score‐matched, real‐world comparison of ustekinumab vs vedolizumab as a second‐line treatment for Crohn’s disease. The Cross Pennine study II

A. de Silvestri, C. Stansfield, C. Selinger, 2021, Alimentary pharmacology & therapeutics.